New combo aims to cure hepatitis b without lifelong pills
NCT ID NCT07069569
First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times
Summary
This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the blood, allowing patients to safely stop their daily antivirals. Participants will be monitored for 24 weeks after stopping all treatment to check if the virus stays undetectable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AHB-137 injection, hepatitis B vaccine, pegylated interferon α-2b
- What this could lead to
- If successful, this combination could help people with chronic hepatitis B stop long-term antiviral medication and achieve a functional cure (no detectable virus).
- What could go wrong
- This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. The treatment involves multiple drugs and may cause side effects like flu-like symptoms or injection reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
AusperBio Investigational Site
RECRUITINGChongqing, Chongqing Municipality, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGFuzhou, Fujian, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGGuangzhou, Guangdong, China
-
AusperBio Investigational Site
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGShenzhen, Guangdong, China
-
AusperBio Investigational Site
RECRUITINGShenzhen, Guangdong, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGZunyi, Guizhou, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGWuhan, Hubei, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGChangchun, Jilin, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGChengdu, Sichuan, China
-
AusperBio Investigational Site
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGKunming, Yunnan, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data